Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C22H30N4O2S2 |
| Molecular Weight | 446.629 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)S(=O)(=O)C1=CC2=C(SC3=C(C=CC=C3)N2CCCN4CCN(C)CC4)C=C1
InChI
InChIKey=VZYCZNZBPPHOFY-UHFFFAOYSA-N
InChI=1S/C22H30N4O2S2/c1-23(2)30(27,28)18-9-10-22-20(17-18)26(19-7-4-5-8-21(19)29-22)12-6-11-25-15-13-24(3)14-16-25/h4-5,7-10,17H,6,11-16H2,1-3H3
DescriptionSources: https://www.drugbank.ca/drugs/DB01622Curator's Comment: description was created based on several sources, including
https://www.drugs.com/international/thioproperazine.html | https://www.ncbi.nlm.nih.gov/pubmed/13661859 | https://www.ncbi.nlm.nih.gov/pubmed/16777448 | https://www.ncbi.nlm.nih.gov/pubmed/1354163 | https://www.ncbi.nlm.nih.gov/pubmed/4379824 | http://eci2012.net/wp-content/uploads/2015/03/Majeptil-PM-En-160702.01-20Feb2015.pdf
Sources: https://www.drugbank.ca/drugs/DB01622
Curator's Comment: description was created based on several sources, including
https://www.drugs.com/international/thioproperazine.html | https://www.ncbi.nlm.nih.gov/pubmed/13661859 | https://www.ncbi.nlm.nih.gov/pubmed/16777448 | https://www.ncbi.nlm.nih.gov/pubmed/1354163 | https://www.ncbi.nlm.nih.gov/pubmed/4379824 | http://eci2012.net/wp-content/uploads/2015/03/Majeptil-PM-En-160702.01-20Feb2015.pdf
Thioproperazine is a potent neuroleptic with antipsychotic properties. Thioproperazine has a marked cataleptic and antiapomorphine activity associated with relatively slight sedative, hypothermic and spasmolytic effects. It is virtually without antiserotonin and hypotensive action and has no antihistaminic property. It is used for the treatment of all types of acute and chronic schizophrenia, including those which did not respond to the usual neuroleptics; manic syndromes. Overdosage may result in severe extrapyramidal symptoms with dysphagia, marked sialorrhea, persistent and rapidly increasing hyperthermia, pulmonary syndrome, state of shock with pallor and profuse sweating, which may be followed by collapse and coma.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL217 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16777448 |
0.45 nM [Ki] | ||
Target ID: CHEMBL234 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1354163 |
1.2 nM [Ki] | ||
Target ID: CHEMBL224 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16288681 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Majeptil Approved UseINDICATIONS. All types of acute and chronic schizophrenia, including those which did not respond to the usual neuroleptics; manic syndromes. |
|||
| Primary | Majeptil Approved UseINDICATIONS. All types of acute and chronic schizophrenia, including those which did not respond to the usual neuroleptics; manic syndromes. |
|||
| Primary | Majeptil Approved UseINDICATIONS. All types of acute and chronic schizophrenia, including those which did not respond to the usual neuroleptics; manic syndromes. |
Doses
| Dose | Population | Adverse events |
|---|---|---|
160 mg 1 times / day multiple, oral Highest studied dose Dose: 160 mg, 1 times / day Route: oral Route: multiple Dose: 160 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
|
30 mg 3 times / day multiple, oral Recommended Dose: 30 mg, 3 times / day Route: oral Route: multiple Dose: 30 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Disc. AE: Excitement, Dysphagia... AEs leading to discontinuation/dose reduction: Excitement (2.2%) Sources: Dysphagia (2.2%) |
90 mg 1 times / day multiple, oral Recommended Dose: 90 mg, 1 times / day Route: oral Route: multiple Dose: 90 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Disc. AE: Neurologic symptoms, Hypertonia... AEs leading to discontinuation/dose reduction: Neurologic symptoms (grade 3) Sources: Hypertonia (grade 3) Dysphagia Autonomic dysfunction QT interval prolonged Ventricular arrhythmia Torsade de pointes Tardive dyskinesia Neuroleptic malignant syndrome Stroke Venous thromboembolism |
15 mg 3 times / day multiple, oral Studied dose Dose: 15 mg, 3 times / day Route: oral Route: multiple Dose: 15 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
Disc. AE: Seizures... AEs leading to discontinuation/dose reduction: Seizures (1.8%) Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Dysphagia | 2.2% Disc. AE |
30 mg 3 times / day multiple, oral Recommended Dose: 30 mg, 3 times / day Route: oral Route: multiple Dose: 30 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Excitement | 2.2% Disc. AE |
30 mg 3 times / day multiple, oral Recommended Dose: 30 mg, 3 times / day Route: oral Route: multiple Dose: 30 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Autonomic dysfunction | Disc. AE | 90 mg 1 times / day multiple, oral Recommended Dose: 90 mg, 1 times / day Route: oral Route: multiple Dose: 90 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Dysphagia | Disc. AE | 90 mg 1 times / day multiple, oral Recommended Dose: 90 mg, 1 times / day Route: oral Route: multiple Dose: 90 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Neuroleptic malignant syndrome | Disc. AE | 90 mg 1 times / day multiple, oral Recommended Dose: 90 mg, 1 times / day Route: oral Route: multiple Dose: 90 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| QT interval prolonged | Disc. AE | 90 mg 1 times / day multiple, oral Recommended Dose: 90 mg, 1 times / day Route: oral Route: multiple Dose: 90 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Stroke | Disc. AE | 90 mg 1 times / day multiple, oral Recommended Dose: 90 mg, 1 times / day Route: oral Route: multiple Dose: 90 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Tardive dyskinesia | Disc. AE | 90 mg 1 times / day multiple, oral Recommended Dose: 90 mg, 1 times / day Route: oral Route: multiple Dose: 90 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Torsade de pointes | Disc. AE | 90 mg 1 times / day multiple, oral Recommended Dose: 90 mg, 1 times / day Route: oral Route: multiple Dose: 90 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Venous thromboembolism | Disc. AE | 90 mg 1 times / day multiple, oral Recommended Dose: 90 mg, 1 times / day Route: oral Route: multiple Dose: 90 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Ventricular arrhythmia | Disc. AE | 90 mg 1 times / day multiple, oral Recommended Dose: 90 mg, 1 times / day Route: oral Route: multiple Dose: 90 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Hypertonia | grade 3 Disc. AE |
90 mg 1 times / day multiple, oral Recommended Dose: 90 mg, 1 times / day Route: oral Route: multiple Dose: 90 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Neurologic symptoms | grade 3 Disc. AE |
90 mg 1 times / day multiple, oral Recommended Dose: 90 mg, 1 times / day Route: oral Route: multiple Dose: 90 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Seizures | 1.8% Disc. AE |
15 mg 3 times / day multiple, oral Studied dose Dose: 15 mg, 3 times / day Route: oral Route: multiple Dose: 15 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Methotrimeprazine-induced corneal deposits and cataract revealed by urine drug profiling test. | 2010-11 |
|
| Research on antipsychotics in India. | 2010-01 |
|
| An overview of Indian research in schizophrenia. | 2010-01 |
|
| Relationship between obesity and antipsychotic drug use in the adult population: a longitudinal, retrospective claim database study in Primary Care settings. | 2008-02 |
|
| Simple and simultaneous determination for 12 phenothiazines in human serum by reversed-phase high-performance liquid chromatography. | 2007-07-01 |
|
| Analysis of phenothiazines in human body fluids using disk solid-phase extraction and liquid chromatography. | 2006-03-11 |
|
| Correlative neuroanatomical and neuropharmacological study of tremor and catatonia in the monkey. | 1971-05 |
|
| The bucco-linguo-masticatory syndrome as a side-effect of neuroleptics therapy. | 1967 |
Patents
Sample Use Guides
Adults: It is recommended to start treatment at a low dosage of about 5 mg per day in a single dose or in divided doses. This initial dosage is gradually increased by the same amount every 2 to 3 days until the usual effective dosage of 30 to 40 mg per day is reached. In some cases higher dosages of 90 mg or more per day, are necessary to control the psychotic manifestations. Children: In children over 10 years: Start treatment with a daily dosage of 1 to 3 mg following the method of treatment described for adults.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3926530
The effects of drugs on biochemical parameters of red blood cells were assessed using 100 ml human blood, which was obtained from a volunteer and diluted with 15 ml of 16 mM citric acid, 113 mM sodium citrate, 21 mM monosodium phosphate, 140 mM glucose, and 2 mM adenine at pH 7.4. Thioproperazine samples were added to 10-ml aliquots of blood to give a final concentration of 1 mM, and the blood was stored at 4 C. The pH of the blood was routinely measured, and 2-ml samples were taken. The cells were pelleted by centrifugation at 3000gma x for 5 rain, and the supernatants were removed. Two volumes of 15% (w/v) trichloroacetic acid were added to 1 vol of packed cells and, after standing on ice for 10 rain, the denatured protein was removed by centrifugation. The acid-soluble fraction was extracted four times with copious amounts of water-saturated diethyl ether to remove the trichloracetic acid and was assayed for 2,3-diphosphoglyceric acid levels using spectrophotometric methods
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QN05AB08
Created by
admin on Mon Mar 31 18:06:17 GMT 2025 , Edited by admin on Mon Mar 31 18:06:17 GMT 2025
|
||
|
NCI_THESAURUS |
C29710
Created by
admin on Mon Mar 31 18:06:17 GMT 2025 , Edited by admin on Mon Mar 31 18:06:17 GMT 2025
|
||
|
WHO-ATC |
N05AB08
Created by
admin on Mon Mar 31 18:06:17 GMT 2025 , Edited by admin on Mon Mar 31 18:06:17 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB10983MIG
Created by
admin on Mon Mar 31 18:06:17 GMT 2025 , Edited by admin on Mon Mar 31 18:06:17 GMT 2025
|
PRIMARY | |||
|
59120
Created by
admin on Mon Mar 31 18:06:17 GMT 2025 , Edited by admin on Mon Mar 31 18:06:17 GMT 2025
|
PRIMARY | |||
|
2635
Created by
admin on Mon Mar 31 18:06:17 GMT 2025 , Edited by admin on Mon Mar 31 18:06:17 GMT 2025
|
PRIMARY | |||
|
100000082127
Created by
admin on Mon Mar 31 18:06:17 GMT 2025 , Edited by admin on Mon Mar 31 18:06:17 GMT 2025
|
PRIMARY | |||
|
10498
Created by
admin on Mon Mar 31 18:06:17 GMT 2025 , Edited by admin on Mon Mar 31 18:06:17 GMT 2025
|
PRIMARY | RxNorm | ||
|
911
Created by
admin on Mon Mar 31 18:06:17 GMT 2025 , Edited by admin on Mon Mar 31 18:06:17 GMT 2025
|
PRIMARY | |||
|
9429
Created by
admin on Mon Mar 31 18:06:17 GMT 2025 , Edited by admin on Mon Mar 31 18:06:17 GMT 2025
|
PRIMARY | |||
|
m10780
Created by
admin on Mon Mar 31 18:06:17 GMT 2025 , Edited by admin on Mon Mar 31 18:06:17 GMT 2025
|
PRIMARY | Merck Index | ||
|
316-81-4
Created by
admin on Mon Mar 31 18:06:17 GMT 2025 , Edited by admin on Mon Mar 31 18:06:17 GMT 2025
|
PRIMARY | |||
|
DB01622
Created by
admin on Mon Mar 31 18:06:17 GMT 2025 , Edited by admin on Mon Mar 31 18:06:17 GMT 2025
|
PRIMARY | |||
|
YJ050AQ56X
Created by
admin on Mon Mar 31 18:06:17 GMT 2025 , Edited by admin on Mon Mar 31 18:06:17 GMT 2025
|
PRIMARY | |||
|
DTXSID1023655
Created by
admin on Mon Mar 31 18:06:17 GMT 2025 , Edited by admin on Mon Mar 31 18:06:17 GMT 2025
|
PRIMARY | |||
|
C084825
Created by
admin on Mon Mar 31 18:06:17 GMT 2025 , Edited by admin on Mon Mar 31 18:06:17 GMT 2025
|
PRIMARY | |||
|
206-262-4
Created by
admin on Mon Mar 31 18:06:17 GMT 2025 , Edited by admin on Mon Mar 31 18:06:17 GMT 2025
|
PRIMARY | |||
|
C73292
Created by
admin on Mon Mar 31 18:06:17 GMT 2025 , Edited by admin on Mon Mar 31 18:06:17 GMT 2025
|
PRIMARY | |||
|
THIOPROPERAZINE
Created by
admin on Mon Mar 31 18:06:17 GMT 2025 , Edited by admin on Mon Mar 31 18:06:17 GMT 2025
|
PRIMARY | |||
|
CHEMBL609109
Created by
admin on Mon Mar 31 18:06:17 GMT 2025 , Edited by admin on Mon Mar 31 18:06:17 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)